Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
262
resultados
Última actualización
26/04/2026 [07:43:00]
Resumen de: US20260110699A1
0000 A method for detection or monitoring status of traumatic brain injury (TBI) and/or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP/FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP/FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.
Resumen de: US20260109740A1
The disclosure provides, in various embodiments, polynucleotides comprising a polyamine-responsive element and a reporter protein coding sequence encoding a reporter protein, wherein interaction between a polyamine and the polyamine-responsive element modulates expression of the reporter protein. The disclosure also provides, in various embodiments, vectors cells, and kits comprising the polynucleotides, methods of reporting an intracellular polyamine, and methods of detecting and/or reporting an intracellular polyamine analog.
Resumen de: AU2024342922A1
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
Resumen de: US20260109946A1
The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.
Resumen de: US20260110700A1
Provided are methods and kits for blood sample collection, protein extraction, and analysis of neuro biomarkers obtained from blood samples on dried blood drop cards.
Resumen de: US20260110682A1
0000 Methods for identifying agents or manipulations that modulate copper (Cu) dyshomeostasis in an Mblac1- or swip-10-dependent manner, and for identifying agents that support Cu-dependent neuronal health in a subject are provided.
Resumen de: US20260110685A1
Disclosed herein are methods for analyzing quantitative expression values of biomarkers of a biomarker panel for determining disease activity in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of predictive models for determining disease activity in human subjects based on the quantitative expression values of the markers.
Resumen de: EP4729947A2
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.
Resumen de: EP4729943A2
0001 Disclosed herein are improved methods of assessing Glial fibrillary acidic protein (GFAP) status in a subject (such as for examples, as a measure of traumatic brain injury or for other clinical reasons).
Resumen de: EP4729538A2
0001 The present invention relates to Tau-binding antibodies and binding fragments thereof.
Resumen de: US20260103683A1
The disclosure relates to methods of generating at least one brain organoid-sufficient embryoid body or repairing at least one non-viable embryoid body, the method comprising incubating a population of induced pluripotent stem cells (iPSCs) in an embryoid body formation medium (EB FM), the EB FM comprising a culture medium, glutamine, recombinant human insulin, recombinant human transferrin, sodium selenite, and thermostable fibroblast growth factor 2 (FGF2). The disclosure further relates to methods of generating brain organoids from brain organoid-sufficient embryoid bodies and repairing embryoid bodies.
Resumen de: US20260102391A1
The present disclosure relates generally to methods of inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular organisms, to methods of identifying agents which inhibit such complex and to the medical use of those agents. Inhibition of the VOR complex causes interference with at least one mechanism of intercellular communication, wherein the intercellular communication is mediated by receptor-ligand interaction and/or EVs, and viral infection involving the transport of endocytosed biomaterials to the nucleus of recipient cells.
Resumen de: US20260104419A1
Disclosed herein are methods for detecting or determining an amount, quantity, concentration and/or level of an anti-transcription factor A, mitochondrial (TFAM) antibody, such as an anti-human TFAM antibody, in one or more biologics samples obtained from a subject. In some aspects, the methods relate to identifying a subject suffering from systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome that is at risk of thrombosis, malignancy, death or any combination thereof.
Resumen de: WO2026079284A1
Disclosed is a method for quantifying DOPA decarboxylase in a biological sample. The method includes bringing the biological sample into contact with a first anti-DOPA decarboxylase antibody or an antigen-binding fragment thereof.
Resumen de: WO2026076634A1
Provided are Aβ375 related oligomers/aggregates in human brains and anti-Aβ3175 related oligomers/aggregates antibodies thereof. In addition, the using of anti-Aβ3175 related oligomers/aggregates antibodies for the treatment of Alzheimer's disease (AD) is also provided.
Resumen de: US20260102478A1
The invention is directed to immunological compositions of one or more peptides containing epitopes of PGN, LTA and LPS molecules that induce an immunological response in a mammal, and to multiple antibodies that bind to these epitopes. Immunological compositions and antibodies disclosed herein can be used in the treatment and/or prevention of human health disorders such as bacterial sepsis, inflammation, cancers, tumors, inflammatory diseases and disorders, and neurodegenerative disorders such as, but not limited to Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and/or limbic predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260103494A1
This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vector; and vectors or compositions for use in the treatment of AP-4-Hereditary Spastic Paraplegia.
Resumen de: CN117761317A
According to the method, system, composition and kit for diagnosis and differential diagnosis of the Alzheimer's disease based on human brain hippocampus space transcriptomics, differential diagnosis of the Alzheimer's disease is achieved through one or more of CCK, Neurogranin and PMP2 carried by plasma extracellular vesicles (EVs). The core detection technology of the application is a nanoflow detection technology, focuses on clinical and scientific research problems of early diagnosis and differential diagnosis of AD cognitive impairment, and performs high-sensitivity and high-throughput detection on nervous system source EVs in peripheral blood through an international leading space transcriptome and single cell sequencing and a brand-new nanoflow detection technology; the method has the advantages of high speed and low cost, utilizes human brain resources, innovatively discovers the EVs markers of the brain region and cell specific sources of the central nervous system, realizes rapid and efficient early diagnosis and differential diagnosis of AD cognitive impairment, and provides a new technical means and method for clinical application of clinical AD cognitive impairment and large-scale screening related accurate diagnosis work.
Resumen de: WO2024258729A2
This document provides methods and materials for assessing and/or treating mammals having a paraneoplastic neurologic syndrome (PNS). For example, methods and materials for using a Sloan Kettering virus family transcriptional corepressor 2 (SKOR2) polypeptide and/or one or more fragments of a SKOR2 polypeptide to detect the presence or absence of autoantibodies present in immune-mediated PNS are provided.
Resumen de: WO2024165736A1
Disclosed herein are methods and agents for the treatment and/or prevention of cyclin dependent kinase like 5 (CDKL5) deficiency disorder. In particular, disclosed herein are compounds or compositions for increasing cyclin dependent kinase like 2 (CDKL2) in a subject, such as in the brain of a subject, and the use of those compounds and compositions in methods of treating CDKL5 deficiency disorder
Resumen de: KR102543112B1
The present invention relates to a method for detecting particles of a substance to be analyzed present in a minimum amount in a fluid sample. The method comprises the steps of: flowing a fluid sample containing a substance to be analyzed, on a substrate having an array of microchambers to the surface of which a first capture material specifically binding to the substance to be analyzed is fixed; allowing the substance to be analyzed to bind to the first capture material in each microchamber of the array of microchambers; flowing a second capture material specifically binding to the substance to be analyzed and binding to a signal generating material, on the substrate to react the substance to be analyzed with the second capture material; flowing the signal generating material on the substrate to bind to the second capture material; flowing, on the substrate, a substrate solution reacting with the signal generating material to generate a fluorescent signal; flowing a hydrophobic solvent on the substrate, and removing the substrate solution outside the microchamber when the signal generating material and the substrate solution react with each other inside the microchamber; and counting the number of microchambers in which the fluorescent signal has occurred, and detecting the same. Therefore, the concentration of molecules or particles present in a minimum amount in a fluid sample can be more easily calculated.
Resumen de: EP3842452A1
The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.
Resumen de: WO2024189211A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: JP2026510789A
本発明は、ＰＡＭの立体構造エピトープに対する少なくとも１つの結合剤を含むアッセイを使用して、体液又は組織試料中のＰＡＭ及び／又はそのアイソフォーム及び／又はその断片のレベルを決定するための方法、並びに診断目的のためのその使用を対象とする。【選択図】なし
Nº publicación: JP2026511083A 10/04/2026
Solicitante:
フジレビオユーロープナームローゼフェンノートシャップ
Resumen de: WO2024200207A1
A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.
BOPI
Sede Electrónica
